Background: Tumor stage predicts pancreatic cancer (PDAC) prognosis, but prolonged and
short survivals have been described in patients with early-stage tumors. Circulating …

Background. Identifying diagnostic and prognostic biomarkers that could be targeted in the
therapy of pancreatic cancer is essential. Objective. Investigations were conducted with …

There is an urgent need for novel and reliable biomarkers for the diagnosis and
prognostication of pancreatic ductal adenocarcinoma (PDAC). Circulating microRNAs …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive cancers
with a less than 6% five-year survival rate. Circulating microRNAs (miRNAs) are emerging …

Pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge due to its poor
prognosis. Therefore, the early diagnosis of PDAC is extremely important for achieving a …

Pancreatic cancer (PC) is considered to be the seventh most common cause of cancer-
related deaths. The number of deaths caused by PC is estimated to increase in the future …

The differential expression of microRNAs (miRNAs) in plasma of pancreatic cancer (PC)
patients may act as a diagnostic biomarker. A four-stage study was performed to identify …

Blood plasma microRNAs (miRNAs) are emerging as a clinically useful tool for non-invasive
detection and prognosis estimation in various cancer types including pancreatic ductal …

BACKGROUND Detection of pancreatic cancer (PaC), particularly at early stages, remains a
great challenge owing to lack of specific biomarkers. We sought to identify a PaC-specific …

Currently, the majority of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC)
present with locally invasive and/or metastatic disease, resulting in five-year survival of less …